A study by Prins and colleagues found that neoadjuvant anti-PD1 induces T-cell and cDC1 activation in patients with recurrent GBM however, this treatment modality failed to overcome immunosuppressive tumor associated macrophages that have a large presence in the TME of patients with GBM (74). The gene discussed is MPPE1; the disease is glioblastoma.